• PDF / 169,690 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 42 Downloads / 155 Views

DOWNLOAD

REPORT

---

1 S

Neurotoxicity and thrombocytopenia: case report A 73-year-old man developed neurotoxicity and thrombocytopenia during treatment with gemcitabine and oxaliplatin for metastatic pancreatic adenosquamous carcinoma (PASC) [routes, duration of treatments to reactions onset and outcomes not stated]. The man, who was diagnosed with metastatic PASC, started receiving systemic chemotherapy with GEMOX regimen comprised of gemcitabine 1000 mg/m2 on day 1 and oxaliplatin 100 mg/m2 on days 1 and 2 every 2 weeks in August 2007, which was scheduled to receive for 12 cycles. However, he developed grade 2 neurotoxicity and grade 2 thrombocytopenia associated with GEMOX regimen. Therefore, the man’s treatment with GEMOX regimen was interrupted. Thereafter, he started receiving monotherapy with gemcitabine 1000 mg/m2 every 3 weeks. Overall, he well tolerated the GEMOX regimen and gemcitabine monotherapy, with only neurotoxicity and thrombocytopenia associated with GEMOX regimen. A remarkable reduction of the abdominal pain and improvement in his quality of life was noted. In October 2007, an almost complete response was obtained to chemotherapy with GEMOX regimen and gemcitabine monotherapy. He showed the response till April 2009 when the progression was noted. Subsequently, gemcitabine monotherapy was discontinued. Eventually, in January 2010 he died [exact cause of death not stated] Aurilio G, et al. Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma. Tumori 97: 239-242, No. 2, Apr 2011. Available from: 803500454 URL: http://doi.org/10.1177/030089161109700220

0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Sep 2020 No. 1821